Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • Platseebo 80mg kõvakapsel Läbipaistmatu, želatiinist kõvakapsel suurusega 2, valge kapslikeha ja valge kapslikaanega, sisaldab glükoosi Placebo will be produced by East Tallinn-Central Hospital Pharmacy.Registry product

    Linked study entry; product equivalence not established

    Formulation reported by source: N/A

    View study and source

Success Metrics

Active Trials
1(100%)

Phase Distribution

Phase 4
1
100%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution1 total trials
Phase 4Post-market surveillance
1(100.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

1

all time

Status Distribution
Active(1)

Detailed Status

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
1
Active
1
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 41 (100.0%)

Trials by Status

active_not_recruiting1100%

Recent Activity

1 active trials
Showing 1 of 1
active_not_recruitingphase_4

The efficacy of aprepitant for the prevention of postoperative nausea and vomiting after bariatric surgery.

SYF608c77c7bb874995af4e4c7062738ba1

Clinical Trials (1)

Showing 1 of 1 trials
SYF608c77c7bb874995af4e4c7062738ba1Phase 4

The efficacy of aprepitant for the prevention of postoperative nausea and vomiting after bariatric surgery.

Active Not Recruiting

All 1 trials loaded

Drug Details

Intervention Type
Type not reported
Total Trials
1